Ultimovacs ASA

Oslo Stock Exchange ULTI.OL

Ultimovacs ASA Total Non-Current Liabilities for the year ending December 31, 2024

Ultimovacs ASA Total Non-Current Liabilities is NA for the year ending December 31, 2024. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Ultimovacs ASA Total Non-Current Liabilities for the year ending December 31, 2023 was USD 1.33 M, a -9.55% change year over year.
Ultimovacs ASA Total Non-Current Liabilities for the year ending December 31, 2022 was USD 1.47 M, a 12.95% change year over year.
Ultimovacs ASA Total Non-Current Liabilities for the year ending December 31, 2021 was USD 1.30 M, a -19.51% change year over year.
Ultimovacs ASA Total Non-Current Liabilities for the year ending December 31, 2020 was USD 1.62 M, a 7.93% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Oslo Stock Exchange: ULTI.OL

Ultimovacs ASA

CEO	Dr. Carlos de Sousa
IPO Date	June 3, 2019
Location	Norway
Headquarters	Ullernchausséen 64
Employees	17
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Key trends

Past 5 years